HomeEverythingEducation
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Praxis Precision Medicines Reports Phase 2/3 POWER1 Study Findings

Created at 6 Jun · 12:48 AM1 source↑ Market-relevant
IN SHORT

Praxis Precision Medicines announced findings from its Phase 2/3 POWER1 study evaluating ulixacaltamide for paroxysmal kinesigenic dyskinesia.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Who's Involved

Praxis Precision Medicines
Biopharmaceutical company announcing study findings

↳ Why This Matters

The study findings are crucial for determining the future development path of ulixacaltamide and could impact the company's pipeline and potential treatments for patients with paroxysmal kinesigenic dyskinesia.

Key facts

  • Praxis Precision Medicines announced Phase 2/3 POWER1 study findings.
  • The study evaluated ulixacaltamide for paroxysmal kinesigenic dyskinesia.
  • Results from the clinical trial are now available.

Praxis Precision Medicines has announced the findings from its Phase 2/3 POWER1 study. This clinical trial was designed to evaluate the efficacy of ulixacaltamide in patients diagnosed with paroxysmal kinesigenic dyskinesia. The study's results are now available.

Frequently asked questions

Praxis Precision Medicines is a biopharmaceutical company focused on developing treatments for central nervous system disorders.

The study focused on paroxysmal kinesigenic dyskinesia, a neurological disorder characterized by sudden, involuntary movements.

The drug evaluated in the study was ulixacaltamide.

What Happens Next

01Further analysis of study results.
02Potential decisions on advancing ulixacaltamide to further clinical trial phases or regulatory submissions.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence
CME Headlines
  • New Product Summary: Initial Listing of Fifty-Five (55) Single Stock Futures Contracts — Effective July 27, 2026
    27 Jul · 4:32 PM
  • New Product Summary: Initial Listing of Twenty-Two (22) Micro Single Stock Futures Contracts - Effective July 27, 2026
    27 Jul · 4:11 PM
  • Initial Listing of Additional Event Contract Swaps on Pro Golf Tournaments
    9 Jul · 9:41 AM

How It Developed

5 Jun · 3:55 PM
Praxis Precision Medicines announced Phase 2/3 POWER1 study findings evaluating ulixacaltamide for paroxysmal kinesigenic dyskinesia.
Yahoo News | Finance Top Stories via PiQSuite

Sources

T1
Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findingsm.piqsuite.com

Related Stories

Michael Burry Buys Flutter, DraftKings Shares on Prediction Market Threat
8 Jul · 9:51 PM
Honeywell Technologies raises 2026 profit targets after reverse stock split
8 Jul · 9:08 PM
Zhipu AI Shares Rise After Lockup Expiry Amid Investor Support
8 Jul · 8:25 PM
SK Hynix $28B ADR bookbuild closes Wednesday amid strong demand
8 Jul · 7:57 AM
JPMorgan Hires Michael Flynn to Lead New Small-Cap Banking Business
8 Jul · 3:03 PM